The weight loss landscape has changed dramatically. GLP-1 receptor agonists — a class of medications originally developed for Type 2 diabetes — have become the most effective pharmaceutical tools for long-term weight management. Two medications now dominate the conversation: semaglutide and tirzepatide. But understanding which one is right for you requires more than reading headlines.

Here’s what the clinical data actually shows, how these medications differ, and what to consider before starting treatment.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a natural hormone that regulates appetite and blood sugar. When administered as a weekly injection, these medications reduce hunger, slow gastric emptying, and help the brain register fullness more effectively.

The result: patients eat less without the constant battle against cravings that undermines traditional dieting.

Two FDA-approved options have emerged as the leading choices for weight loss:

• Semaglutide — the active ingredient in Ozempic (approved for diabetes) and Wegovy (approved for weight loss)

• Tirzepatide — the active ingredient in Mounjaro (diabetes) and Zepbound (weight loss)

Both are administered as once-weekly subcutaneous injections and follow a gradual dose-escalation protocol over several months.

How Semaglutide Works

Semaglutide targets a single receptor — the GLP-1 receptor — to suppress appetite and improve metabolic function. It has been studied extensively, with clinical trials showing average weight loss of 15-17% of body weight over 68 weeks.

The STEP trials, published in the New England Journal of Medicine, demonstrated that patients on semaglutide 2.4mg lost an average of 14.9% of their body weight compared to 2.4% with placebo. For a 250-pound individual, that translates to roughly 37 pounds.

Semaglutide dosages typically start at 0.25mg weekly and gradually increase to a maintenance dose of up to 2.4mg, depending on tolerability and clinical response.
Best suited for: Patients new to GLP-1 therapy, those with moderate weight loss goals (BMI 27-35), and patients who prefer the longer safety track record.

How Tirzepatide Works

Tirzepatide takes a dual-action approach, targeting both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism appears to produce greater appetite suppression and improved insulin sensitivity compared to GLP-1-only medications.

The SURMOUNT-1 trial showed that patients on tirzepatide 15mg achieved average weight loss of 22.5% of body weight — significantly higher than semaglutide’s results in comparable trials. For the same 250-pound individual, that’s approximately 56 pounds.

Tirzepatide dosages start at 2.5mg weekly and can increase to 15mg based on the patient’s response and tolerance.

Best suited for: Patients with higher BMI (35+), those who haven’t achieved adequate results with semaglutide, and patients seeking maximum weight loss.

Head-to-Head: Semaglutide vs. Tirzepatide



Both medications share a similar side effect profile — primarily gastrointestinal symptoms (nausea, diarrhea, constipation) that tend to diminish as the body adjusts during dose escalation. Neither medication should be used during pregnancy or by patients with a personal or family history of medullary thyroid carcinoma.


Telehealth provider reviewing patient data

The Cost Question

Brand-name GLP-1 medications are expensive. Wegovy and Zepbound can exceed $1,000 per month without insurance, and coverage remains inconsistent. This has driven significant demand for compounded versions — pharmacy-prepared formulations of the same active ingredients at a fraction of the retail cost.
Telehealth platforms have emerged to bridge this gap, offering medical oversight combined with more accessible pricing. The model is straightforward: patients complete a health assessment, a licensed provider reviews their medical history and determines eligibility, and approved patients receive medication shipped directly to their home.

Weight Method (weightmethod.com) is one of the platforms built around this model — combining clinical technology with medical expertise to simplify access to GLP-1 treatment. Patients complete a comprehensive health assessment, and a proprietary matching algorithm paired with licensed provider review determines which medication and dosage fits their profile. The platform offers both semaglutide and tirzepatide, with the clinical decision driven by data — BMI, health history, comorbidities, and weight loss goals — not marketing.

“The choice between semaglutide and tirzepatide should be a medical conversation, not a guessing game,” says Raul Danglade, founder of Weight Method. “We built the platform so that technology handles the complexity — risk stratification, dosage protocols, progress tracking — while licensed providers focus on the medicine. A patient with a BMI of 28 has very different needs than someone with a BMI of 40 and comorbidities. The system accounts for that.”

With over 47,000 members across all 50 states, the platform reports patients averaging 12 pounds of weight loss in their first month — results it attributes to the combination of evidence-based prescribing and ongoing clinical support built into every plan.

How to Decide: Five Questions to Ask

Before choosing between semaglutide and tirzepatide, patients should consider:

1. What is your BMI? Patients with BMI 27-34 may see excellent results with semaglutide. Those with BMI 35+ may benefit more from tirzepatide’s stronger efficacy profile.

2. Have you used GLP-1 medications before? Patients who plateaued on semaglutide often see renewed progress when switching to tirzepatide’s dual-receptor mechanism.

3. How do you tolerate GI side effects? Both medications cause nausea during dose escalation. Patients with sensitive stomachs may prefer semaglutide’s more gradual titration schedule.

4. What does your provider recommend? This should not be a self-directed decision. A licensed medical provider should evaluate your full health picture — including diabetes status, cardiovascular health, current medications, and prior weight loss attempts.

5. What can you sustain long-term? GLP-1 medications are most effective as part of an ongoing treatment plan. Consider pricing, convenience, and whether the program offers continued medical support beyond the initial prescription.

The Bigger Picture

GLP-1 medications represent a genuine shift in how medicine approaches obesity — moving from willpower-based interventions to evidence-based pharmacotherapy that addresses the biological mechanisms driving weight gain.

But medication alone is not a complete solution. The most successful outcomes combine GLP-1 therapy with dietary awareness, physical activity, and consistent medical follow-up. Programs that provide ongoing provider access and dosage management — rather than simply shipping medication — tend to produce better long-term adherence and results.

For patients considering GLP-1 treatment, the first step is a medical evaluation. Whether through a primary care physician or a telehealth platform like Weight Method, that conversation ensures the right medication, the right dose, and the right support system are in place from day one.
________________________________________
Weight Method is a technology-driven weight loss platform connecting patients with licensed providers who prescribe FDA-approved GLP-1 medications — semaglutide and tirzepatide — nationwide. Learn more at weightmethod.com.